An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 5, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
Primary Open-Angle GlaucomaOcular Hypertension
Interventions
DRUG

Bimatoprost

Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.

Trial Locations (10)

27517

UNC Kittner Eye Center, Chapel Hill

30076

Coastal Research Associates, Atlanta

30260

Clayton Eye Center, Morrow

45243

Apex Eye, Madeira

63131

Ophthalmology Consultants, St Louis

76102

Ophthalmology Associates PC, Fort Worth

90701

Sall Medical Research Center, Artesia

92037

Scripps Clinic Torrey Pines, La Jolla

92663

Eye Research Foundation, Newport Beach

95817

UC Davis Dept of Ophthalmology & Vision Science, Sacramento

All Listed Sponsors
lead

ForSight Vision5, Inc.

INDUSTRY

NCT02143843 - An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product | Biotech Hunter | Biotech Hunter